
    
      PLB1001 will be administrated 200mg twice daily. The treatment will be discontinued for the
      patients who experience disease progression, death, adverse event (AE) leading to
      discontinuation or withdrawal of consent. A cycle of study treatment will be defined as 28
      days of continuous dosing. The study includes 4 cohorts.
    
  